Insmed (INSM) EBIT (2010 - 2026)

Insmed's EBIT history runs 17 years deep, the most recent figure standing at -$153.3 million for Q1 2026.

• In Q1 2026, EBIT rose 38.21% year-over-year to -$153.3 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 17.44% YoY), while the FY2025 annual figure was -$1.2 billion, down 41.96% from the prior year.
• EBIT was -$153.3 million for Q1 2026 at Insmed, up from -$319.7 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$88.3 million in Q2 2022 to a low of -$366.0 million in Q3 2025.
• Historically, EBIT has averaged -$202.7 million across 5 years, with a median of -$178.3 million in 2023.
• The sharpest annual moves came in 2023 and 2026: EBIT slumped 166.69% in 2023, then soared 38.21% in 2026.
• A 5-year view of EBIT shows it stood at -$151.5 million in 2022, then slipped by 17.69% to -$178.3 million in 2023, then slipped by 29.25% to -$230.4 million in 2024, then plunged by 38.77% to -$319.7 million in 2025, then surged by 52.05% to -$153.3 million in 2026.
• The last three EBIT figures came in at -$153.3 million (Q1 2026), -$319.7 million (Q4 2025), and -$366.0 million (Q3 2025), per Business Quant data.